Mi Kyong Joung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mi Kyong Joung has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Kyong Ran Peck
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
14 shared publications Doo Ryeon Chung
Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 shared publicationsJae-Hoon Song
Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
7 shared publicationsCheol-In Kang
Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
5 shared publications- Cheol-In Kang
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
5 shared publications Jeong-A Lee
Division of Infectious Diseases, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea
5 shared publications
Latest Publications
- Open Access
- 1 October 2017
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 92 (5) , 471-475
Adrenal Gland Metastasis of a Gastrointestinal Stromal Tumor
- 1 October 2017
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 92 (5) , 471-475
Open AccessAdrenal Gland Metastasis of a Gastrointestinal Stromal Tumor
- Open Access
- 1 March 2016
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 90 (3) , 266-269
Bordetella bronchiseptica Respiratory Infection in the Immunosuppressed Patient
- 1 March 2016
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 90 (3) , 266-269
Open AccessBordetella bronchiseptica Respiratory Infection in the Immunosuppressed Patient
- Open Access
- 1 February 2016
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 90 (2) , 173-176
Gas Gangrene Caused by Streptococcus anginosus
- 1 February 2016
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 90 (2) , 173-176
Open AccessGas Gangrene Caused by Streptococcus anginosus
- Open Access
- 1 January 2016
- Published by XMLink in Infection & Chemotherapy
- Vol. 48 (2) , 118-126
Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea
Choi WS, et al. Infect Chemother. 2016 Jun;48(2):118-126. https://doi.org/10.3947/ic.2016.48.2.118
- 1 January 2016
- Published by XMLink in Infection & Chemotherapy
- Vol. 48 (2) , 118-126
Open AccessClinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea
Choi WS, et al. Infect Chemother. 2016 Jun;48(2):118-126. https://doi.org/10.3947/ic.2016.48.2.118
- 1 January 2015
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 81 (1) , 60-65
Anti-anaerobic coverage is not necessary for Klebsiella pneumoniae liver abscess: a propensity score–matched cohort study
- 1 January 2015
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 81 (1) , 60-65
Anti-anaerobic coverage is not necessary for Klebsiella pneumoniae liver abscess: a propensity score–matched cohort study
- Open Access
- 1 January 2014
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 7 (3) , 229-231
Nasal Deformity Due to Tuberculous Chondritis
Moon SY, et al. Clin Exp Otorhinolaryngol. 2014 Sep;7(3):229-231. http://dx.doi.org/10.3342/ceo.2014.7.3.229
- 1 January 2014
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 7 (3) , 229-231
Open AccessNasal Deformity Due to Tuberculous Chondritis
Moon SY, et al. Clin Exp Otorhinolaryngol. 2014 Sep;7(3):229-231. http://dx.doi.org/10.3342/ceo.2014.7.3.229
- 1 December 2012
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 18 (6) , 562-566
Clinical Experience of Tigecycline Treatment in Infections Caused by Extensively Drug-Resistant Acinetobacter spp.
Background: Tigecycline has broad spectrum antimicrobial activity and is approved for complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired pneumonia. There are few data on clinical experience of tigecycline in hospital-acquired pneumonia (HAP) and Acinetobacter spp. infection. Methods: A retrospective study was performed at eight hospitals in Korea from May 2009 to January 2010. Adult patients treated with tigecycline regardless of their source of infection or pathogens were enrolled. Results: Tigecycline was administered in 108 patients. Pneumonia was the most common infection (43.5%), followed by skin and soft tissue infections (20.4%). Acinetobacter baumannii was isolated from 83 patients (76.9%) accounting for 50.3% of isolated pathogens, showing a resistance rate of 67.5% to carbapenems. Superinfection was identified in 32 patients (29.6%). Pseudomonas aeruginosa was most common microorganism causing superinfection (46.9%). Overall 30-day mortality rate was 52.9%. Thirty-day mortality rate of HAP and Acinetobacter spp. infection was 60.5% and 59.4%, respectively. Conclusion: Tigecycline can be considered as an alternative therapy in patients with HAP or infections caused by Acinetobacter spp., especially extensively drug-resistant A. baumannii .
- 1 December 2012
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 18 (6) , 562-566
Clinical Experience of Tigecycline Treatment in Infections Caused by Extensively Drug-Resistant Acinetobacter spp.
Background: Tigecycline has broad spectrum antimicrobial activity and is approved for complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired pneumonia. There are few data on clinical experience of tigecycline in hospital-acquired pneumonia (HAP) and Acinetobacter spp. infection. Methods: A retrospective study was performed at eight hospitals in Korea from May 2009 to January 2010. Adult patients treated with tigecycline regardless of their source of infection or pathogens were enrolled. Results: Tigecycline was administered in 108 patients. Pneumonia was the most common infection (43.5%), followed by skin and soft tissue infections (20.4%). Acinetobacter baumannii was isolated from 83 patients (76.9%) accounting for 50.3% of isolated pathogens, showing a resistance rate of 67.5% to carbapenems. Superinfection was identified in 32 patients (29.6%). Pseudomonas aeruginosa was most common microorganism causing superinfection (46.9%). Overall 30-day mortality rate was 52.9%. Thirty-day mortality rate of HAP and Acinetobacter spp. infection was 60.5% and 59.4%, respectively. Conclusion: Tigecycline can be considered as an alternative therapy in patients with HAP or infections caused by Acinetobacter spp., especially extensively drug-resistant A. baumannii .
- Open Access
- 1 January 2012
- Published by Korean Society of Infectious Diseases and Korean Society for Chemotherapy in Infection & Chemotherapy
- Vol. 44 (6) , 446-449
A Case of Acute Transverse Myelitis Associated with Neurosyphilis
Lee CB, et al. Infect Chemother. 2012 Dec;44(6):446-449. https://doi.org/10.3947/ic.2012.44.6.446
- 1 January 2012
- Published by Korean Society of Infectious Diseases and Korean Society for Chemotherapy in Infection & Chemotherapy
- Vol. 44 (6) , 446-449
Open AccessA Case of Acute Transverse Myelitis Associated with Neurosyphilis
Lee CB, et al. Infect Chemother. 2012 Dec;44(6):446-449. https://doi.org/10.3947/ic.2012.44.6.446
- Open Access
- 2 March 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (2) , 1-8
Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia
Introduction: De-escalation therapy is a strategy currently used for the management of nosocomial pneumonia. In this study, we evaluated clinical outcomes and risk factors related to de-escalation therapy in patients with intensive care unit (ICU)-acquired pneumonia. Methods: This was a retrospective observational cohort study of ICU patients who developed pneumonia more than 48 hours after admission to the ICU at Samsung Medical Center from September 2004 to December 2007. Results: The 137 patients comprised 44 (32.1%) who received de-escalation therapy and 93 in the non-de-escalation group. The de-escalation group showed a lower pneumonia-related mortality rate than the non-de-escalation group by day 14 (2.3% vs. 10.8%, respectively; P = 0.08) and by day 30 (2.3% vs. 14%, respectively; P = 0.03) after the diagnosis of pneumonia. The variables independently associated with ICU-acquired pneumonia-related mortality included the Acute Physiology and Chronic Health Evaluation II (APACHE II) score and the modified Clinical Pulmonary Infection Score (CPIS) after 5 days with pneumonia. The non-de-escalation group had significantly higher APACHE II score and modified CPIS after 5 days with ICU-acquired pneumonia compared to the de-escalation group. Among all patients, 20.4% (28 of 137) had negative cultures for pathogens, and 42.9% (12 of 28) received de-escalation therapy. The latter 12 patients received de-escalation therapy and survived 30 days after the diagnosis of pneumonia. Conclusions: Patients in the de-escalation group showed a significantly lower mortality rate compared to patients in the non-de-escalation group. De-escalation therapy can be safely provided to patients with ICU-acquired pneumonia if they are clinically stable by day 5, even in those whose respiratory specimen cultures yield no specific pathogens.
- 2 March 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (2) , 1-8
Open AccessImpact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia
Introduction: De-escalation therapy is a strategy currently used for the management of nosocomial pneumonia. In this study, we evaluated clinical outcomes and risk factors related to de-escalation therapy in patients with intensive care unit (ICU)-acquired pneumonia. Methods: This was a retrospective observational cohort study of ICU patients who developed pneumonia more than 48 hours after admission to the ICU at Samsung Medical Center from September 2004 to December 2007. Results: The 137 patients comprised 44 (32.1%) who received de-escalation therapy and 93 in the non-de-escalation group. The de-escalation group showed a lower pneumonia-related mortality rate than the non-de-escalation group by day 14 (2.3% vs. 10.8%, respectively; P = 0.08) and by day 30 (2.3% vs. 14%, respectively; P = 0.03) after the diagnosis of pneumonia. The variables independently associated with ICU-acquired pneumonia-related mortality included the Acute Physiology and Chronic Health Evaluation II (APACHE II) score and the modified Clinical Pulmonary Infection Score (CPIS) after 5 days with pneumonia. The non-de-escalation group had significantly higher APACHE II score and modified CPIS after 5 days with ICU-acquired pneumonia compared to the de-escalation group. Among all patients, 20.4% (28 of 137) had negative cultures for pathogens, and 42.9% (12 of 28) received de-escalation therapy. The latter 12 patients received de-escalation therapy and survived 30 days after the diagnosis of pneumonia. Conclusions: Patients in the de-escalation group showed a significantly lower mortality rate compared to patients in the non-de-escalation group. De-escalation therapy can be safely provided to patients with ICU-acquired pneumonia if they are clinically stable by day 5, even in those whose respiratory specimen cultures yield no specific pathogens.
- Open Access
- 1 January 2011
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 49 (5) , 305-307
Concurrent Nocardia Related Brain Abscess and Semi-Invasive Pulmonary Aspergillosis in an Immunocompetent Patient
We describe here the first case of a concurrent brain abscess caused by Norcardia spp. and semi-invasive pulmonary aspergillosis in an immunocompetent patient. After one year of appropriate antimicrobial therapy and surgical drainage of the brain abscess, the nocardia brain abscess and pulmonary aspergillosis have resolved.
- 1 January 2011
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 49 (5) , 305-307
Open AccessConcurrent Nocardia Related Brain Abscess and Semi-Invasive Pulmonary Aspergillosis in an Immunocompetent Patient
We describe here the first case of a concurrent brain abscess caused by Norcardia spp. and semi-invasive pulmonary aspergillosis in an immunocompetent patient. After one year of appropriate antimicrobial therapy and surgical drainage of the brain abscess, the nocardia brain abscess and pulmonary aspergillosis have resolved.